Finance

Lists
TKPHF:OTCMKTS
Takeda Pharmaceutical Co Ltd
$ 36.78
+0.07%
(+0.025) 1D
$ 35.82
-2.61% (-0.96)
After hours
Closed: 10-р сарын 2, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TKPHF...
Open
$ 36.78
High
$ 36.78
Low
$ 36.78
Mkt. cap
56.97 тэрбум
Avg. vol.
2.11 мян
Volume
13.12 мян
52-wk high
$ 39.20
52-wk low
$ 26.33
Beta
-2.60
Shares outstanding
1.60 тэрбум
No. of employees
47 мян
Open
$ 36.78
High
$ 36.78
Low
$ 36.78
Mkt. cap
56.97 тэрбум
Avg. vol.
2.11 мян
Volume
13.12 мян
52-wk high
$ 39.20
52-wk low
$ 26.33
Beta
-2.60
Shares outstanding
1.60 тэрбум
No. of employees
47 мян
News stories
From web sources and news partners
Stock Traders Daily
Stock Traders Daily
·
1 өдрийн өмнө
(TAK) Movement Within Algorithmic Entry Frameworks
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47 мян
Founded1781 оны 6-р сарын 12
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
1.11ИН
1.19ИН
1.09ИН
1.22ИН
Cost of goods sold
380.06Т
401.15Т
453.33Т
406.68Т
Cost of revenue
380.06Т
401.15Т
453.33Т
406.68Т
Research and development expenses
161.48Т
175.23Т
187.96Т
167.40Т
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
253.55Т
282.78Т
291.96Т
286.51Т
Operating expense
562.57Т
661.30Т
519.65Т
612.60Т
Total operating expenses
942.63Т
1.06ИН
972.98Т
1.02ИН
Operating income
170.17Т
129.25Т
121.56Т
200.62Т
Other non operating income
77.96 тэрбум
-197.22Т
181.53Т
-28.14 тэрбум
EBT including unusual items
28.17 тэрбум
133.86Т
-455.02Т
162.72Т
EBT excluding unusual items
128.86Т
114.17Т
71.49 тэрбум
161.92Т
Income tax expense
39.90 тэрбум
30.13 тэрбум
-86.62 тэрбум
49.46 тэрбум
Effective tax rate
141.64%
22.51%
19.04%
30.40%
Other operating expenses
16.12 тэрбум
67.13 тэрбум
-64.27 тэрбум
53.17 тэрбум
Net income
-11.80 тэрбум
103.64Т
-368.47Т
113.20Т
Net profit margin
-1.06%
8.70%
-33.66%
9.28%
Earnings per share
-
-
-
-
Interest and investment income
43.92 тэрбум
181.35Т
-
24.61 тэрбум
Interest expense
-161.10Т
-
-239.63Т
-35.70 тэрбум
Net interest expenses
-117.18Т
181.35Т
-239.63Т
-11.09 тэрбум
Depreciation and amortization charges
-
-
-
-
EBITDA
355.15Т
319.89Т
192.73Т
363.66Т
Gain or loss from assets sale
303.00 сая
358.00 сая
1.46 тэрбум
-6.00 тэрбум
AI content may include mistakes. Learn more
Google аппс